Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tivozanib for Recurrent Glioblastoma

This study has been completed.
Sponsor:
Collaborator:
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Elizabeth R. Gerstner, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01846871
First received: May 1, 2013
Last updated: December 1, 2016
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2016
  Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: December 1, 2016